#### SYNTHESIS, CHARACTERIZATION AND ANTIMICROBIAL ANALYSIS OF VARIOUS SUBSTITUTED 2-(5-(3-(5-BROMOTHIOPHEN-2-YL)-1-(4-FLUOROPHENYL)-1*H*-PYRAZOL-4-YL)-4,5-DIHYDRO-1*H*-PYRAZOL-3-YL)PHENOL

Shirsat A. J., Rupnar B. D., Bhagat S. S. and Kakade G. K.<sup>1</sup> Department of Chemistry, R. B. Attal College, Georai, Dist. Beed (M. S.) <sup>1</sup>Department of Chemistry, Arts, Commerce & Science College, Kille, Dharur, Dist. Beed (M. S.) shirsatamol222@gmail.com

# ABSTRACT

A series of substituted pyrazolines synthesis, used procedure was a simple, efficient and green. The reaction between acrolein, and  $\alpha$ ,  $\beta$ - enone in presence of phenylhydrazine yield simple pyrazoline via. Cyclization. The easy work-up of product under mild condition with fast reaction this significant feature of synthesis of pyrazolines. Further the structures of pyrazoline derivatives were elucidated by IR, <sup>1</sup>H NMR and mass spectral analysis. The compounds were evaluated for their antibacterial activity using Gram + positive and Gram negative bacteria.

Keywords: Pyrazolines, chalcones, synthesis, spectral data, antibacterial activity.

## INTRODUCTION

Many heterocyclic compounds due to their definite activity are employed in the treatment of several infectious diseases. Their use in the treatment is attributed to their intrinsic toxicity to different pathogens. Among a broad range of heterocyclic compounds that have been explored for the development of pharmaceutically significant molecules, pyrazolines constitute an interesting class of heterocycles due to their synthetic versatility and large variety of biological activities like acyl-CoA inhibitory <sup>1</sup>, antioxidant<sup>2</sup>, anticancer<sup>3</sup>, antifungal<sup>4</sup>, antibacterial<sup>5</sup>, antidepressant<sup>6-8</sup>, anticonvulsant<sup>9</sup>, antiinflammatory<sup>10</sup>, antitumor<sup>11</sup>, analgesic<sup>12</sup>, neuroprotective <sup>13</sup> properties.

### EXPERIMENTAL

For the synthesis of the compounds, all required chemicals were obtained from SD Fine chemicals and Sigma Aldrich. Melting points are uncorrected and were recorded in open capillaries. By using Bruker Avance II 400 MHz NMR Spectrophotometer, solvent is DMSO-d6 and TMS as an internal standard, 1H NMR spectra were recorded. On FT-IR Spectrophotometer Model RZX (Perkin Elmer) on potassium bromide disk, the infra-red spectra were recorded. By using electro-spray method (ES), Mass spectra were recorded on Macromass mass spectrophotometer (Waters). Synthesized compounds purity was checked on TLC plate which is coated by silica gel as stationary phase which is obtained from Merck. In this, mobile phase is solvent mixture of hexane / ethyl acetate (80:20).

### GENERAL PROCEDURE

Compound **1c** Chalcone (0.01mol) was dissolved in 20ml ethanol. To this reacting mixture, 0.02 mol of hydrazine hydrate was slowly added. These contents were heated for 4 hr. under mild reflux and then in to the reaction mixture, glacial acetic acid (4-5 drops) was added and heating was continued to 3hr and then cooled up to room temperature. Cold water (60ml) was slowly added to the flask and product was separated. This product was filtered, washed with cold water for many times and recrystallized in ethanol. The compounds **2(a-g)** were prepared by following above general procedure. Physical data of synthesized compounds are recorded in **Table 1**. Confirmed synthesized compounds structures by <sup>1</sup>HNMR, Mass and IR spectra.

**IR** (2c) (cm<sup>-1</sup>):965(C-Cl), 1070(Ar-Br), 1555(C=C), 1598(C=N), 3121(O-H), 3310(N-H).

<sup>1</sup>**H NMR** (**2c**) (DMSO-d<sub>6</sub>)δ ppm: 3.1124-3.1665(dd, 1H, -CH<sub>a</sub>-, *J*=12.08 Hz & *J*=9.56Hz),

3.5231-3.5713(dd,1H,-CH<sub>b</sub>-, J= 12.12Hz & J=7.16Hz), 4.7452-4.7901(ddd,1H, -CH<sub>c</sub>-, J=6.24Hz, J=7.12Hz & J=5.36Hz), 6.9190-6.9341(d, 1H, -NH-, J=6.04Hz), 7.3218-7.4123(m, 2H, Ar-H), 7.4352-7.5424(m, 1H, Ar-H), 7.6389-7.7093(m, 2H, Ar-H), 7.8326(s, 1H, Ar-H), 7.8587-7.8998(m, 1H, Ar-H), 7.9362(s,1H, Ar-H), 7.9842(s, 1H, Ar-H), 8.5863(s,1H, pyrazole-H), 11.3586(s, 1H, Ar-OH).


**ES-MS** (2c) (m/z):517.2(M+1), 518.2(M+2), 519.2(M+3), 521.2(M+5).

**IR** (2f) (cm<sup>-1</sup>): 955(C-Cl), 1065(Ar-Br), 1575(C=C), 1600(C=N), 3231(O-H), 3342(N-H).

<sup>1</sup>**H NMR** (2**f**) (DMSO-d<sub>6</sub>) $\delta$  ppm: 2.4123(s, 3H, -CH<sub>3</sub>), 3.1293-3.1785(dd, 1H, -CH<sub>a</sub>-, *J*=10.58 Hz & *J*=9.10Hz), 3.4819-3.5211(dd,1H,-CH<sub>b</sub>-, *J*= 8.50Hz & *J*=7.18Hz), 4.7251-4.7552(ddd,1H, -CH<sub>c</sub>-, *J*=4.12Hz, *J*=3.92Hz & *J*=4.00Hz), 6.8970-6.9202(d, 1H, -NH-, *J*=9.2Hz), 7.1987-7.2835(m, 2H, Ar-H), 7.4567-7.5364(m, 1H, Ar-H),

7.5825-7.5998(d, 1H, *J*=6.92 Hz), 7.8254(s, 1H, Ar-H), 7.8325-7.8496(d, 1H, Ar-H, *J*=6.84Hz), 7.8751(s,1H, Ar-H), 7.9053(s, 1H, Ar-H), 8.6587(s,1H, pyrazole-H), 11.8521(s, 1H, Ar-OH).

**ES-MS** (2f) (m/z): 531.1(M+1), 532.1(M+2), 533.1M+3), 535.1(M+5).



l(a-g)

2(a-g)

Scheme-1: Synthesis of various 2-(5-(3-(5-bromothiophen-2-yl)-1-(4-fluorophenyl)-1*H*-pyrazol-4-yl)-4,5dihydro-1*H*-pyrazol-3-yl)phenol

Tuble 11 Hysical data of compounds (24 g)								
Comp.	<b>R</b> <sub>1</sub>	$\mathbf{R}_2$	<b>R</b> <sub>3</sub>	M.P. (°C)	Yield (%)			
2a	Н	Н	Н	162-164	69			
2b	Н	Н	CH <sub>3</sub>	182-184	72			
2c	Н	Н	Cl	190-192	74			
2d	Cl	Н	Cl	180-182	77			
2e	Н	Н	F	212-214	69			
2f	Н	CH <sub>3</sub>	Cl	168-170	81			
2g	Н	Н	Br	206-208	78			

Table-1:	Physical	data	of com	nounds	(2a-g)
I abic-I.	1 Hysical	uata	or com	pounds	( <u>2</u> a- <u>5</u> )

### **RESULT AND DISCUSSION**

The synthetic work was carried out beginning from chalcones with hydrazine hydrate in ethanol by cyclization pyrazolines are formed successfully in moderate to good yields. All newly synthesized compounds were identified on the basis of <sup>1</sup>H NMR, melting point range, Mass spectral analysis & IR. Using disc diffusion method, newly synthesized derivatives were evaluated for antimicrobial activity.

Antimicrobial activity: Compounds 2(a-g) were analyzed for their in vitro antimicrobial activity against *Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 25923), Pseudomonas aeruginosa (ATCC 27853)* by paper disc diffusion method and reference standard drug is Gentamycin. Antifungal activity was analyzed against Candida sp. using Nystatin as standard drug. At 100  $\mu$ g/ml concentration, all the tests were evaluated. Muller Hinton agar was the culture media. The region of inhibition was measured in mm after 24 hr of incubation at 37oC. Microbial data for compounds 2(a-g) are summarized below in Table 2.

Table-2: Antimicrobial Analysis Data								
Sr. No.	Comp. No.	Escherichia coli (ATCC 25922)	Staphylococcus aureus (ATCC 25923)	Pseudomonas aeruginosa (ATCC 27853)	Candida sp.			
1	2a	No Zone	No Zone	No Zone	No Zone			
2	2b	No Zone	No Zone	No Zone	No Zone			
3	2c	No Zone	No Zone	No Zone	No Zone			
4	2d	No Zone	No Zone	No Zone	No Zone			
5	2e	No Zone	No Zone	No Zone	No Zone			
6	2f	No Zone	No Zone	No Zone	No Zone			
7	2g	No Zone	No Zone	No Zone	No Zone			
8	Gentamycin	28 mm	23 mm	32 mm				
9	Nystatin				23 mm			

#### CONCLUSION

Starting from Chalcones 1(a-g), different new cyclized derivatives of pyrazoline have been synthesized to good yield and characterized by IR, <sup>1</sup>HNMR and Mass spectral data. The newly synthesized derivatives of pyrazolines were evaluated against Candida sp. and Gram positive as well as Gram negative bacterial strains.

Volume 6, Issue 2 (XXXIX): April - June, 2019

### ACKNOWLEDGEMENT

The authors are thankful to The Principal Dr. R.K. Nimbalkar for providing laboratory facilities. The authors are thankful to Director, SAIF/CIL, Panjab University, Chandigarh for providing spectral data & thankful to Uday Khedkar, Director, BAC-TEST Laboratory, Nashik for antimicrobial analysis.

#### REFERENCES

- 1. Jeong T.S, Kim K.S, An S.J, Cho K.H, Lee S and Lee W.S (2004) Novel 3,5-diaryl Pyrazolines as Human Acyl-CoA: Cholesterol Acyltransferase Inhibitors. Bioorg. Med. Chem.Lett., 14, 2715–2717.
- 2. Venkatesh P, Hari Prasath K, Sharfudeen S, Soumya V, Spandana V and Priyanka J, (2012), Synthesis of Coumarin fused Pyrazoline-5-one derivatives and Screening for their antimicrobial and antioxidant activity, J Pharm Res., (5(5)), 2875-2877.
- 3. Nimavat K S, Popat K H and Joshi H S, (2003), Synthesis, anticancer, antitubercular and antimicrobial activity of 1-substituted 3-aryl-5-(3'-bromophenyl)-pyrazolines, Indian J Hetrocycl Chem., 12, 225-228.
- 4. Shailesh H S and Pankaj S P, (2012), Synthesis and Biological Activity of Some Novel Phenyl Pyrazoline Derivatives, Chem Sci Trans., (1(3)), 632-637.
- 5. Seham Y H, (2013), Synthesis, Antibacterial and Antifungal Activity of Some New Pyrazoline and Pyrazole Derivatives, Molecules, (18(3)), 2683-2711.
- 6. Palaska E, Aytemir M, Uzbay T and Erol D, Eur, (2001), Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines, J Med Chem., (36(6)), 539-543.
- Rajendra Prasad Y, Lakshmana Rao A, Prasoona L, Murali K and Ravi Kumar P, (2005), Synthesis and antidepressant activity of some 1,3,5-triphenyl-2-pyrazolines and 3-(2"-hydroxy naphthalen-1"-yl)-1,5diphenyl-2-pyrazolines, Bioorg Medl Chem Lett., (15(22)), 5030-5034.
- 8. Palaska E, Erol D and Demirdamar R, (1996), Synthesis and antidepressant activities of some 1,3,5-triphenyl-2-pyrazolines,Eur J Med Chem., (31(1)), 43-47.
- 9. Ramesh B and Sumana T, (2010), Synthesis and Anti-Inflammatory Activity of Pyrazolines, J Chem., (7(2)), 514-516.
- 10. Ozdemir Z, Kandilici B H, Gumucel B, Calis U and Bilgin A A,( 2007), Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives, Eur J Med Chem., (42(3)), 373-379.
- 11. Jainey P J and Bhat I K. (2012), Antitumor, Analgesic, and Anti-inflammatory Activities of Synthesized Novel Pyrazolines, J Young Pharm., (4(2)), 82–87.
- 12. Sridhar S and Rajendraprasad Y, (2012), Synthesis and Analgesic Studies of Some New 2-pyrazolines, J Chem., (9(4)), 1810-1815.
- 13. Camacho M.E, Leon J and Entrena A(2004) 4,5-Dihydro-1*H*-pyrazole Derivatives with Inhibitory nNOS Activity in Rat Brain: Synthesis and Structure-Activity Relationships. J. Med. Chem., 47, 5641-5650.